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Data are presented on the current incidence of melanoma with recent and predicted future trends illustrating a likely
continuing increase in incidence. Risk factors for developing melanoma are discussed, including current known
melanoma susceptibility genes. Phenotypic markers of high-risk subjects include high counts of benign melanocytic
naevi. Other risk factors considered include exposure to natural and artiﬁcial ultraviolet radiation, the effect of female
sex hormones, socioeconomic status, occupation, exposure to pesticides and ingestion of therapeutic drugs including
immunosuppressives and non-steroidal anti-inﬂammatory drugs. Aids to earlier diagnosis are considered, including
public education, screening and use of equipment such as the dermatoscope. Finally, the current pattern of survival
and mortality is described.
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introduction
At the present time, the epidemiology of cutaneous melanoma
is of interest to all those who care for melanoma patients
including surgeons, dermatologists, oncologists and primary
care physicians. This review will highlight current aspects
including the increasing incidence of the disease worldwide,
current recognised risk factors for melanoma and the role that
any of these may play in increasing incidence. The review will
also point out a contrast between small changes in mortality
and much larger changes in incidence. Aids to earlier diagnosis
will be considered, as will the results of recent campaigns aimed
at either primary prevention of melanoma or earlier diagnosis.
current incidence trends
sources of information
The major sources of information on incidence for all cancers
including melanoma are national cancer registries. These have
the advantage of being reasonably comprehensive, but data
tend to be published several years in arrears because of the
workload involved, and data presented tend to be minimal.
Coding systems for national registries separate lentigo maligna
melanoma and lentigo maligna from nodular and superﬁcial
spreading varieties, and there is variation in the recording of
in situ lesions between registries. There is no consistent policy
over recording tumour thickness, exact body site is generally
not recorded and there is inconsistency over registering second
and subsequent primary tumours of the same pathological type.
Specialist melanoma registries record more detail. They may
either concentrate on material referred to one major
institution, or attempt to capture all melanomas in a given
geographic area. Material gathered in such registries is
particularly useful for case–control studies, and also for
recording changes over time in tumour thickness, a possible
surrogate for improving prognosis.
The regular publication of Cancer Incidence in Five
Continents by the International Agency for Research on Cancer
gives a comparative overview of melanoma incidence
worldwide. These volumes aim to record current cancer
incidence ﬁgures adjusted for age to a world-standardised rate,
using material from all cancer registries worldwide that meet
appropriate standards of quality control. The recently
published volume IX covers the period 1998–2002 [1] and
shows that, as in the past, the highest recorded incidence of
invasive cutaneous melanoma worldwide is in Queensland,
Australia, at a ﬁgure of 55.8/10
5/annum for males and 41.1/10
5/
annum for females (Table 1). Even within Australia there is
a clear latitude gradient with incidence ﬁgures per annum in
New South Wales that are 38.5/10
5 for males and 26.5/10
5 for
females, and in Victoria as low as 27.3/10
5 for males and 23.4/
10
5 for females. Incidence ﬁgures are also high for New Zealand
at 34.8/10
5 and 31.4/10
5 per annum for males and females,
respectively. Large numbers of registries from North America
have contributed, and the most useful ﬁgures for the USA are
the SEER results from 14 registries, which show an incidence of
19.4/10
5 and 14.4/10
5 per annum for males and females in non-
Hispanic whites.
Reported incidence rates vary for Europe, and are highest in
Switzerland and the Scandinavian countries of Norway, Sweden
and Denmark. All European countries report a higher incidence
in females than males, in contrast to Australasia and North
America, where males have a higher incidence. Incidence rates
in Europe are higher in the more afﬂuent countries, as
compared with data from the Baltic states of Latvia, Lithuania
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Belarus and Serbia (Table 1), although recent data show a rise
in incidence in many east European countries [2]. Within Italy
there appears to be a latitude gradient, with a higher incidence
in both sexes in northern Italy around Milan compared with
that in the Naples area. Table 1 also shows that, for the time
period studied, the incidence of melanoma in Queensland is
more than three times that of any European country. This will
be discussed further below and should be kept in mind when
considering public education in prevention and early detection
campaigns appropriate for the target population.
incidence ﬁgures from individual cancer registries
and specialist melanoma registries
As stated above, incidence ﬁgures from these sources may not
be strictly comparable between registries because of differing
methods of case ascertainment, geographic area covered and
pathological criteria required for inclusion.
A study from Tauranga, New Zealand, records an extremely
high incidence of invasive melanoma of 79/10
5 in the non-
Maori population for 2003. Possible explanations include a very
fair-skinned population, a climate conducive to year-round
outdoor activities, and possibly also the effects of ozone
depletion [3]. A cohort effect has been well explored in New
South Wales, covering the time period 1983–1996. This report
records a continuing increase in incidence in older males
(‡75 at diagnosis), but a stabilisation in younger males and
an average annual percentage fall of 3.3% in females aged
15–34 [4].
In Europe, national cancer registries show a rising incidence
of melanoma overall during the past two decades. In France,
the incidence increased between 1980 and 2000 in males from
2.4/10
5 to 7.6/10
5 and in females from 3.9/10
5 to 9.5/10
5 per
annum. Tumour thickness is only recorded in one department,
but in that, the proportion of thin melanomas increased [5].
Following incidence in Sweden between 1990 and 1999, the
Swedish Melanoma Group reported 12 533 melanoma patients
diagnosed from 1990 to 1999 with no signiﬁcant incidence
change in this population over the time period [6].
A second Swedish study, which was investigating site-speciﬁc
incidence changes between 1960 and 2004, reported 46 337
melanomas diagnosed during this time period [7]. The greatest
incidence increase in both sexes was on the upper limb,
followed by the trunk and then the lower limb, with trunk
melanomas forming an increasing proportion of all melanomas
in both sexes. Head and neck melanomas increased less rapidly
and more commonly involved those aged ‡70. These data are
presented as evidence of the relative importance of intermittent
recreational sun exposure as an aetiological agent as
compared with continuous sun exposure, as is found on the
head and neck.
The Eurocare working group has studied melanoma
incidence rates and changes in eastern and western Europe
before 1992 [8]. Between 1978 and 1992 incidence rates were
lower in eastern than in western Europe, but melanomas were
thicker. The group also reports the paradox of higher
incidence rates in southern countries of eastern Europe and the
converse in western Europe with higher rates in northern
countries, and it predicts a swing in eastern Europe toward
a pattern similar to that seen in western Europe.
The Scottish Melanoma Group has studied 12 450 cases of
invasive cutaneous melanoma diagnosed from 1979 to 2003,
and it reports a trebling of incidence in males of all ages and
a 2.3-fold increase in females. The steepest rates of increase
are seen in males aged ‡60 at diagnosis, and although the
rate of increasing incidence fell in the period 1990–1999
compared with the period 1980–1989, there is as yet no
evidence of stabilisation of incidence rate in any age group or
either sex [9].
Data on melanoma from the majority of countries thus show
a continuing incidence increase overall, with a slowing of the
rate of increase in the period 1990–2000 compared with the
previous decade in many countries. Differing patterns are
emerging in relation to subjects’ sex and age in that a static or
even falling incidence is observed in younger females in some
countries. In contrast, however, the incidence increase
continues in older males in most countries [9].
The main reason proposed for the general increasing
melanoma incidence over the last 40 years is greater exposure of
pale Caucasian skin to natural ultraviolet (UV) radiation.
Inexpensive ﬂights from high-latitude countries, such as
Scandinavia, to Mediterranean or warmer climates have
become available at all times of the year. Short, intermittent
burning episodes of sun exposure have been identiﬁed by
Elwood et al. [10] as a major melanoma risk factor, so some of
the increase could be attributed to greater opportunities for
burning of pale, non-acclimatised Caucasian skin.
A major problem in linking putative risk factors to diagnosis
of melanoma is the lack of current knowledge on the latent
period between initiating factors such as UV exposure and
clinical appearance of a melanoma. This is thought to be
measured in decades, and therefore Diffey in the UK [11] and
de Vries in the Netherlands [12] predict that melanoma
incidence will continue to increase for at least the next 10 years.
While there is no sound current data on ozone layer changes
Table 1. Comparative melanoma incidence ﬁgures for selected states
and countries worldwide for the time period 1998–2002
a
Country Incidence (per 10
5 subjects)
Male Female
Queensland Australia 55.8 41.1
New South Wales Australia 38.5 26.5
Victoria Australia 27.3 23.4
New Zealand 34.8 31.4
US SEER 14 registries
non-Hispanic whites
19.4 14.4
Switzerland, Vaud 16.6 19.6
Norway 14.2 14.6
Sweden 11.9 12.1
Denmark 11.9 14.1
Latvia 3.2 4.2
Lithuania 3.7 5.2
Estonia 5.3 6.6
Belarus 2.7 3.5
Serbia 3.8 4.8
aData taken from ref. [1].
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risk factors for melanoma
Risk factors for any malignancy can be subdivided into genetic
and environmental with interaction between the two. Table 2
gives a list of both established and also postulated risk factors
for cutaneous melanoma.
Approximately 5% of all invasive cutaneous melanomas
occur in a familial setting with two or more close relatives
affected. This observation indicates that, in a small minority of
melanoma patients, low prevalence/high penetrance genes are
involved. In addition, the typical phenotype of the melanoma
patient, with pale Caucasian skin, red or blond hair and blue
eyes indicates that high prevalence/low penetrance genes such
as MC1R may interact with environmental factors, particularly
with sun exposure.
melanoma susceptibility genes
The work of two international melanoma genetics collaborative
groups, Genomel and Gem, has shown that around one-third
of patients in melanoma families worldwide have an
identiﬁable germline mutation in CDKN2A, a gene important
in controlling entry into the cell cycle. A wide range of
mutations has been reported in these families, with
concentration of speciﬁc mutations in certain geographic areas,
such as the Mediterranean, Sweden and Scotland, indicating the
likely source of the founder mutation (for review see ref. [13]).
Functional studies on some of these mutations have indicated
that they are likely to be a signiﬁcant causative factor in
melanoma development. A second melanoma susceptibility
gene, CDK4, has been identiﬁed in ﬁve families to date
worldwide [14], but in >50% of all families with pathologically
conﬁrmed invasive cutaneous melanomas no putative
responsible gene has yet been identiﬁed. A number of research
groups are currently actively investigating these families for new
melanoma susceptibility genes.
The gene MC1R encodes a protein involved in the
production of eumelanin, which is responsible for dark
colouring, and phaeomelanin, which is responsible for red hair
and freckles. Subjects with red hair have a higher proportion of
three MC1R variants, currently known as red-hair variants, and
it has been a matter of discussion whether these variants are
also more common in non-red-haired patients with sporadic
melanoma [15]. A study from New South Wales in Australia
indicates that in familial melanoma, there is an interaction
between mutated CDKN2A and MC1R [16]. High prevalence/
low penetrance genes such as MC1R are important in that they
may be relevant to a much larger proportion of the melanoma
population compared with the small number of familial cases
with CDKN2A mutations.
Two recent publications also add to the list of possible high
prevalence/low penetrance genetic variations affecting
melanoma risk. The ﬁrst study analysed pooled DNA from two
distinct Australian populations and reported that, in these
populations, common sequence variants on chromosome
20q11.22 confer melanoma susceptibility [17]. These results
require conﬁrmation in a non-Australian population, as well as
identiﬁcation of the likely genes. The second study examined
DNA samples from 2121 European melanoma patients and
40 000 controls and reported pigmentation gene variants ASIP
and TYR associated with melanoma [18]. The ASIP locus
encodes the agouti signalling protein and TYR codes for
tyrosinase, so this report brings a molecular genetic explanation
of the clinical observation of the association between
melanoma, fair skin and fair or red hair.
phenotypic risk factors for melanoma
The likely melanoma patient is a pale-skinned Caucasian.
Studies from Australasia [19], North America [20] and Europe
[21] have all shown that a high count of banal melanocytic
naevi is a major risk factor for sporadic melanoma. Naevus
counts vary according to country; high counts are associated
with UV exposure and may be used as a surrogate marker for
UV-induced cutaneous damage. The presence of large, atypical
naevi, termed dysplastic naevi in pathology, is also an
independent risk factor adding to melanoma risk.
natural UV radiation exposure and melanoma risk
As already stated, short, intense episodes of burning sun
exposure appear to be a signiﬁcant risk factor for melanoma
[10], but cumulative UV exposure over the years may also
contribute to the risk. Studies of place of birth and residence
during the ﬁrst decade of life from Australia [22], Israel [23]
and the USA [24] all record that birth and early life spent in
a high-UV environment increases melanoma risk for the
lifetime of the individual in question. There also appears to be
an interaction between chronic UV exposure and the type of
melanoma that may subsequently develop. The lentigo maligna
variety of melanoma, found most commonly on constantly
exposed body sites such as the face, is associated more with
possible chronic occupational UV exposure than intermittent
burning UV exposure episodes. Whiteman et al. [25] have
taken this observation further and postulated two distinct,
partly UV-induced pathways to melanoma that give rise to
slightly different clinical outcomes. The ﬁrst pathway involves
intense intermittent exposure on the trunk of individuals who
have large numbers of banal naevi and have melanoma
Table 2. Established and postulated risk factors for cutaneous
melanoma
Invasive cutaneous melanoma in one or more ﬁrst-degree relatives.
Previous personal primary invasive melanoma.
Multiple banal melanocytic naevi (>100).
Three or more clinically atypical (dysplastic) naevi.
High solar exposure in early childhood (before age 10).
Pale Caucasian skin (skin type 1 or 2).
Red or blond hair.
Past history of one or more severe blistering sunburns.
Higher socioeconomic group.
Past sunbed use, especially before age 30.
Occupation (airline crew).
Past pesticide exposure.
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probably more related to chronic UV exposure, is found in
older individuals who may have a past history of non-
melanoma skin cancer. These melanomas develop on sun-
damaged, constantly exposed sites. This dual-pathway concept
has been strengthened by the observation of Thomas et al. [26]
that BRAF gene mutations are more likely in melanoma of
younger subjects with large numbers of naevi (type A) than in
lesions on sun-exposed skin of older patients (type B).
artiﬁcial UV radiation exposure and melanoma risk
Over the past two decades, artiﬁcial UV sources in the form of
sunbeds have become widely available for both salon use and
home purchase. A number of case–control studies have
investigated the potential melanoma risk associated with
sunbed use. The results are inconsistent, and interpretation is
complex. Subjects who use sunbeds also tend to expose their
skin to higher quantities of UV from natural sunlight, and
separating the contribution of natural and artiﬁcial UV
exposure to melanoma risk may be impossible. In addition,
recall bias has to be considered as a possible confounding
factor. Most melanoma patients are aware that UV exposure is
a risk factor for melanoma, and are therefore likely to recall
after diagnosis even small numbers of sunbed exposures. This
type of recall is much less likely in the control group. A recent
meta-analysis of sunbed use and melanoma has concluded
that overall sunbed exposure does add to melanoma risk [27].
female sex hormones and melanoma risk
Differing melanoma incidence between males and females, and
the tendency for females to develop excess melanin
pigmentation during periods of hormonal stimulation such as
pregnancy, has led to a number of studies investigating the role
of pregnancy, oral contraceptives and hormone replacement
therapy both as risk factors for melanoma and also as events
that may affect prognosis. Cumulative data from publications
on these topics provide no evidence that prior pregnancy is
a risk factor for melanoma [28]. Similarly, there is no evidence
to indicate that oral contraceptive [29] or hormone
replacement [30] use contributes to melanoma risk, nor that
either factor alters the prognosis for those in whom melanoma
has already been diagnosed.
socioeconomic status
A number of studies have reported that, in contrast to
squamous cell cancer of the skin, melanomas are more
prevalent in the wealthier strata of society. Studies from the
USA and UK [31, 32] show that the incidence of melanoma in
age-matched sections of the population is higher in those with
a larger income and other measures of afﬂuence. This may be
due to the greater opportunity of the more afﬂuent for
recreational sun exposure and sunny holidays in the winter
months.
occupation and melanoma risk
Airline crews, particularly pilots, have been recorded in
a number of studies as having a higher-than-expected incidence
of melanoma [33, 34]. It is suggested that this may be due to
greater opportunities for recreational sun exposure during
regulation breaks between ﬂights in areas of the world with
a high solar exposure.
pesticide exposure
A case–control study comparing melanoma on the palms and
soles in both the UK and Australia observed that melanoma
patients reported greater exposure to pesticides than that
reported by controls [33], and recently, an Italian case–control
study has conﬁrmed higher use of pesticides in a residential
setting in melanoma patients compared with that in controls
[34]. Interpretation of these data is complex, as over the past
decade there have been many regulatory changes in Europe
regarding the range of pesticides available for domestic use.
However, data from these studies indicate that questions
regarding the type and frequency of pesticide use should be
added to future case–control studies.
therapeutic use of non-steroidal anti-inﬂammatory
agents and statins
A recent case–control study of oral non-steroidal anti-
inﬂammatory use in melanoma patients and age-matched
controls indicates that regular use of this class of drugs is
associated with reduced melanoma risk [35]. Further studies
are needed to conﬁrm this ﬁnding. A number of studies have
investigated the possibility of an association between the oral
use of statins and melanoma risk. The most recent study from
the Netherlands indicates no association with melanoma risk,
but does report that melanoma patients using statins have
thinner tumours [36].
melanoma risk after renal transplantation
A number of publications show conﬂicting results concerning
the risk of melanoma developing after renal transplantation
and the necessary immunosuppression. Studies from Sweden
and the Netherlands show no increase in melanoma incidence
over that expected in these countries [37, 38], while studies
from the USA and UK show a signiﬁcantly increased risk,
3.6- and 8-fold higher for US [39] and UK patients [40],
respectively. While some of these differences may relate to time
frames of studies and changes in immunosuppressive regimes
over time, further large long-term contemporary studies are
required to determine the degree of increased cutaneous
surveillance required for transplant patients.
approaches aimed at achieving earlier
diagnosis
public education, screening and visual aids to
earlier melanoma recognition
Over the past two decades, a number of public education
exercises have been carried out aimed at increasing general
knowledge about melanoma and, in particular, at helping the
general public recognise early melanoma and seek medical
advice. The objective is to have melanomas removed at an
earlier growth stage when they are thinner and, therefore, have
a better prognosis. This approach was pioneered by the
Annals of Oncology
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both Europe and the USA. Data from Europe indicate that
before such activities, there was poor knowledge of melanoma
and, therefore, long delays between noting a new or changing
pigmented lesion on the skin and seeking medical advice [41].
After such campaigns this type of patient delay reduced
signiﬁcantly, and the proportion of patients with thinner
melanomas and thus better prognoses increased [42]. Earlier
public recognition of melanoma concentrates on simple
guidelines aimed mainly at superﬁcial spreading lesions, which
are the bulk of primary tumours. These guides include the
US-based ABCDEs of melanoma recognition and the Glasgow
7-point checklist (Table 3). Other useful, simple aids to earlier
diagnosis include the so called ‘ugly duckling’ sign [43],
signifying a pigmented lesion that is clearly distinct from other
pigmented lesions on the same body site.
Screening exercises have concentrated on the offer of a free
skin examination and advice to consult the participants’ regular
medical attendants if a suspicious pigmented lesion is
identiﬁed. The offer of a free skin check, often labelled
‘melanoma Monday’, has been popular in both the USA [44]
and countries in Europe [45], where it has been adopted
with large numbers of the public attending. This has been
excellent publicity and a good opportunity for education on
recognising melanoma, among other skin lesions, but the
number of pathologically proven melanomas calculated per
attendee is low in relation to the screened population. In the
USA, a comprehensive review of the results of the AAD
annual free skin check reported a yield of one melanoma per
667 participants [44], while in Belgium, the reported yield
was one melanoma per 110 participants [45]. A report
from the UK [46] gives a yield of one melanoma per 277
participants and concludes that rapid access to pigmented
lesion clinics is a more cost-effective approach in its healthcare
system.
Population-based screening has also been considered in
Australia. A randomised trial of population screening was
carried out in small Queensland towns, where some residents
were selected for the screening, and compared with control
towns, where mass screening was not offered [47, 48]. Results
indicated a greater public interest in screening and self-
examination, but the original plan to extend the work to
a larger national trial has been abandoned because of cost. If the
cost of such an exercise is prohibitive in the country with
the highest incidence of melanoma worldwide, it is unlikely to
be practical in countries with lower incidence.
visual aids to earlier diagnosis
A number of attempts have been made to increase the ease with
which professionals, either dermatologists or general
practitioners, can recognise melanoma at an early growth stage.
The simplest of these is the hand-held dermatoscope, which
enables the observer to examine and photograph cutaneous
lesions at 5- to 25-fold magniﬁcations. With this level of
magniﬁcation, a number of surface features, such as pattern of
melanin pigment spread around the lesion and erythema due to
inﬂammation, can be visualised. Although these machines are
now common in many European countries, there is little
published data on their efﬁcacy compared with naked eye
examination. Available data indicate that training in
dermatoscope use improves both sensitivity and speciﬁcity of
clinical diagnosis by non-expert clinicians, but without
training, preoperative diagnostic accuracy is reduced [49, 50].
More sophisticated equipment with the same aim involves
computerised image analysis using machines such as the
SIAscope and MoleMate. These machines are still under
evaluation, and trials are required to establish whether they
improve sensitivity or speciﬁcity of melanoma diagnosis in the
hands of both well-trained dermatologists and less-experienced
general physicians. A recent trial of the SIAscope in the setting
of a pigmented lesion specialist clinic in northern England
showed no diagnostic beneﬁt compared with the clinical
judgement of trained dermatologists [51]. A further trial
assessing the value of the same machine in a general practice
setting is currently in progress.
mortality, survival and factors inﬂuencing survival
Mortality ﬁgures over the past two decades show trends that
differ from those for incidence, with a much lower rate of
mortality increase than that recorded for incidence. This is well
illustrated in Figure 1, which charts UK ﬁgures for incidence
and mortality together for the 30-year period between 1975 and
2005, covering a population of 55 million.
In Scotland, melanoma mortality in males doubled between
1979 and 2003, a time period during which incidence tripled. In
females in Scotland, mortality has remained constant, while
incidence doubled [9]. Similar data are reported from other
countries, and in Scandinavia in recent years a fall in
melanoma-speciﬁc mortality has been recorded in younger
females. This pattern of divergence between incidence and
Table 3. ABCDE(s) of melanoma and Glasgow 7-point checklist to assist
accurate preoperative diagnosis of cutaneous malignant melanoma
ABCDE Glasgow 7-point checklist
A – asymmetry Three major points Four minor points
B – border irregularity Change in size Diameter ‡6m m
C – colour variation Change in shape Oozing or crusting
D – diameter ‡6 mm Change in colour Inﬂammation
E – elevation or enlargement
or exudation
Itch
0
2
4
6
8
10
12
14
16
1
9
7
5
1
9
7
7
1
9
7
9
1
9
8
1
1
9
8
3
1
9
8
5
1
9
8
7
1
9
8
9
1
9
9
1
1
9
9
3
1
9
9
5
1
9
9
7
1
9
9
9
2
0
0
1
2
0
0
3
2
0
0
5
Year of diagnosis/death
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0
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0
0
0
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Figure 1. Age-standardised incidence and mortality rates of malignant
melanoma in Great Britain between 1975 and 2005.
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attributed to earlier detection of thinner tumours. Scottish data
show improving 5-year survival in each quinquennium between
1979 and 1998 (Table 4), which also illustrates the better
survival for females in each thickness grouping over this time
period. This superior female survival in Scotland has been
conﬁrmed in Dutch patients and also shown to be independent
of tumour thickness, histological type or body site of
tumour [52].
Data from France for the period 1969–1997 show a 2.7- and
2.9-fold mortality increase in females and males, respectively
[5], and Swedish data show decreased mortality between 1990
and 1999 compared with previous time periods [6]. A report
from southern Germany concerning a cohort of 4791 patients
and covering the time period 1976–2001 shows signiﬁcantly
improved survival in the time period 1990–2001 compared
with 1976–1989 [53]. The authors of this paper speculate that
improvements in surgical approaches, a greater use of adjuvant
therapy and greater public awareness leading to earlier
diagnosis may have contributed to this improvement.
concluding remarks
At the start of the 21st century, melanoma remains a potentially
fatal malignancy giving rise to continuing concern for
a number of reasons. At a time when the incidence of many
tumour types is decreasing, melanoma incidence continues to
increase. Much of this increase is seen in relatively young
adults, and consequently the number of life years lost per
melanoma death is higher than that for most other solid
tumours. Although mortality data indicate that extensive public
education campaigns have been at least partially effective in
encouraging earlier self-referral of thinner melanomas with
a better prognosis, few data indicate that primary prevention
campaigns have had a substantial effect. These are mainly
aimed at encouraging safe and reasonable sun exposure habits
according to the latitude of the country in question and the
skin type of the individual. More work is needed on the
psychological factors leading to inappropriate sun exposure so
that future campaigns may be more effective.
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